BioCentury
ARTICLE | Clinical News

Prometic's Ryplazim gets rare pediatric disease designation

September 1, 2017 3:16 PM UTC

Prometic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) said FDA granted rare pediatric disease designation to Ryplazim to treat congenital plasminogen deficiency. The human plasma-derived plasminogen also has Orphan Drug and Fast Track designations from FDA...

BCIQ Company Profiles

Liminal BioSciences Inc.